Cargando…

Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma

Cancer antigen 15–3 (CA15-3) is widely utilized for monitoring metastatic breast cancer (BC). However, its utility for early detection of breast cancer is severely limited due to poor clinical sensitivity and specificity. The glycosylation of CA15-3 is known to be affected by BC, and therefore it mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Terävä, Joonas, Tiainen, Leena, Lamminmäki, Urpo, Kellokumpu-Lehtinen, Pirkko-Liisa, Pettersson, Kim, Gidwani, Kamlesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658058/
https://www.ncbi.nlm.nih.gov/pubmed/31344060
http://dx.doi.org/10.1371/journal.pone.0219480
_version_ 1783438904215470080
author Terävä, Joonas
Tiainen, Leena
Lamminmäki, Urpo
Kellokumpu-Lehtinen, Pirkko-Liisa
Pettersson, Kim
Gidwani, Kamlesh
author_facet Terävä, Joonas
Tiainen, Leena
Lamminmäki, Urpo
Kellokumpu-Lehtinen, Pirkko-Liisa
Pettersson, Kim
Gidwani, Kamlesh
author_sort Terävä, Joonas
collection PubMed
description Cancer antigen 15–3 (CA15-3) is widely utilized for monitoring metastatic breast cancer (BC). However, its utility for early detection of breast cancer is severely limited due to poor clinical sensitivity and specificity. The glycosylation of CA15-3 is known to be affected by BC, and therefore it might offer a way to construct CA15-3 glycovariant assays with improved cancer specificity. To this end, we performed lectin-based glycoprofiling of BC-associated CA15-3. CA15-3 expressed by a BC cell line was immobilized on microtitration wells using an anti-CA15-3 antibody. The glycosylation of the immobilized CA15-3 was then detected by using lectins coated onto europium (III)-doped nanoparticles (Eu(+3)-NPs) and measuring the time-resolved fluorescence of Eu. Out of multiple lectin-Eu(+3)-NP preparations, wheat germ agglutinin (WGA) and macrophage galactose-type lectin (MGL) -Eu(3+)-NPs bound to the BC cell line-dericed CA15-3 glycovariants (CA15-3(Lectin)). To evaluate the clinical performance of these two lectin-based assays, plasma samples from metastatic BC patients (n = 53) and healthy age-matched women (n = 20).Plasma CA15-3(Lectin) measurements better distinguished metastatic BC patients from healthy controls than the conventional CA15-3 immunoassay. At 90% specificity, the clinical sensitivity of the assays was 66.0, 67.9 and 81.1% for the conventional CA15-3, CA15-3(MGL) and CA15-3(WGA) assays, respectively. Baseline CA15-3(MGL) and CA15-3(WGA) were correlated to conventional baseline CA15-3 levels (r = 0.68, p<0.001, r = 0.90, p>0.001, respectively). However, very low baseline CA15-3(MGL) levels ≤ 5 U/mL were common in this metastatic breast cancer patient population.In conclusion, the new CA15-3(Lectin) concept could considerably improve the clinical sensitivity of BC detection compared to the conventional CA15-3 immunoassays and should be validated further on a larger series of subjects with different cancer subtypes and stages.
format Online
Article
Text
id pubmed-6658058
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-66580582019-08-07 Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma Terävä, Joonas Tiainen, Leena Lamminmäki, Urpo Kellokumpu-Lehtinen, Pirkko-Liisa Pettersson, Kim Gidwani, Kamlesh PLoS One Research Article Cancer antigen 15–3 (CA15-3) is widely utilized for monitoring metastatic breast cancer (BC). However, its utility for early detection of breast cancer is severely limited due to poor clinical sensitivity and specificity. The glycosylation of CA15-3 is known to be affected by BC, and therefore it might offer a way to construct CA15-3 glycovariant assays with improved cancer specificity. To this end, we performed lectin-based glycoprofiling of BC-associated CA15-3. CA15-3 expressed by a BC cell line was immobilized on microtitration wells using an anti-CA15-3 antibody. The glycosylation of the immobilized CA15-3 was then detected by using lectins coated onto europium (III)-doped nanoparticles (Eu(+3)-NPs) and measuring the time-resolved fluorescence of Eu. Out of multiple lectin-Eu(+3)-NP preparations, wheat germ agglutinin (WGA) and macrophage galactose-type lectin (MGL) -Eu(3+)-NPs bound to the BC cell line-dericed CA15-3 glycovariants (CA15-3(Lectin)). To evaluate the clinical performance of these two lectin-based assays, plasma samples from metastatic BC patients (n = 53) and healthy age-matched women (n = 20).Plasma CA15-3(Lectin) measurements better distinguished metastatic BC patients from healthy controls than the conventional CA15-3 immunoassay. At 90% specificity, the clinical sensitivity of the assays was 66.0, 67.9 and 81.1% for the conventional CA15-3, CA15-3(MGL) and CA15-3(WGA) assays, respectively. Baseline CA15-3(MGL) and CA15-3(WGA) were correlated to conventional baseline CA15-3 levels (r = 0.68, p<0.001, r = 0.90, p>0.001, respectively). However, very low baseline CA15-3(MGL) levels ≤ 5 U/mL were common in this metastatic breast cancer patient population.In conclusion, the new CA15-3(Lectin) concept could considerably improve the clinical sensitivity of BC detection compared to the conventional CA15-3 immunoassays and should be validated further on a larger series of subjects with different cancer subtypes and stages. Public Library of Science 2019-07-25 /pmc/articles/PMC6658058/ /pubmed/31344060 http://dx.doi.org/10.1371/journal.pone.0219480 Text en © 2019 Terävä et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Terävä, Joonas
Tiainen, Leena
Lamminmäki, Urpo
Kellokumpu-Lehtinen, Pirkko-Liisa
Pettersson, Kim
Gidwani, Kamlesh
Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma
title Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma
title_full Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma
title_fullStr Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma
title_full_unstemmed Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma
title_short Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma
title_sort lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (ca15-3) in human plasma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658058/
https://www.ncbi.nlm.nih.gov/pubmed/31344060
http://dx.doi.org/10.1371/journal.pone.0219480
work_keys_str_mv AT teravajoonas lectinnanoparticleassaysfordetectingbreastcancerassociatedglycovariantsofcancerantigen153ca153inhumanplasma
AT tiainenleena lectinnanoparticleassaysfordetectingbreastcancerassociatedglycovariantsofcancerantigen153ca153inhumanplasma
AT lamminmakiurpo lectinnanoparticleassaysfordetectingbreastcancerassociatedglycovariantsofcancerantigen153ca153inhumanplasma
AT kellokumpulehtinenpirkkoliisa lectinnanoparticleassaysfordetectingbreastcancerassociatedglycovariantsofcancerantigen153ca153inhumanplasma
AT petterssonkim lectinnanoparticleassaysfordetectingbreastcancerassociatedglycovariantsofcancerantigen153ca153inhumanplasma
AT gidwanikamlesh lectinnanoparticleassaysfordetectingbreastcancerassociatedglycovariantsofcancerantigen153ca153inhumanplasma